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Abstract
Background: Delivery of small interfering RNA (siRNA) to tumours remains a major obstacle for the development
of RNA interference (RNAi)-based therapeutics. Following the promising pre-clinical and clinical results with the
oncolytic herpes simplex virus (HSV) OncoVEX
GM-CSF, we aimed to express RNAi triggers from oncolytic HSV, which
although has the potential to improve treatment by silencing tumour-related genes, was not considered possible
due to the highly oncolytic properties of HSV.
Methods: To evaluate RNAi-mediated silencing from an oncolytic HSV backbone, we developed novel replicating
HSV vectors expressing short-hairpin RNA (shRNA) or artificial microRNA (miRNA) against the reporter genes green
fluorescent protein (eGFP) and b-galactosidase (lacZ). These vectors were tested in non-tumour cell lines in vitro
and tumour cells that are moderately susceptible to HSV infection both in vitro and in mice xenografts in vivo.
Silencing was assessed at the protein level by fluorescent microscopy, x-gal staining, enzyme activity assay, and
western blotting.
Results: Our results demonstrate that it is possible to express shRNA and artificial miRNA from an oncolytic HSV
backbone, which had not been previously investigated. Furthermore, oncolytic HSV-mediated delivery of RNAi
triggers resulted in effective and specific silencing of targeted genes in tumour cells in vitro and tumours in vivo,
with the viruses expressing artificial miRNA being comprehensibly more effective.
Conclusions: This preliminary data provide the first demonstration of oncolytic HSV-mediated expression of shRNA
or artificial miRNA and silencing of targeted genes in tumour cells in vitro and in vivo. The vectors developed in
this study are being adapted to silence tumour-related genes in an ongoing study that aims to improve the
effectiveness of oncolytic HSV treatment in tumours that are moderately susceptible to HSV infection and thus,
potentially improve response rates seen in human clinical trials.
Background
RNA interference (RNAi) has emerged not only as a
powerful tool in functional genomics and the validation
of novel gene targets in drug discovery, but also as a
potential therapeutic strategy for diverse diseases,
including cancer [1]. RNAi is a post-transcriptional gene
silencing mechanism mediated by small double-stranded
RNA (dsRNA) molecules, including small interfering
RNAs (siRNAs) and microRNAs (miRNAs) [2-6]. In
mammalian cells, RNAi can be induced by synthetic siR-
NAs introduced directly into the cell or by plasmid and
viral vectors that express short-hairpin RNA (shRNA) or
artificial miRNAs, which have been termed the new
generation RNAi triggers [7-9].
Although a variety of strategies, such as chemical
modifications, liposomes, nanoparticles, and antibodies
or cell-surface receptors, have been employed to
increase siRNA stability and delivery to specific cell
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obstacle for the development of RNAi-based cancer
therapeutics. As a more efficient alternative, replication-
defective viral vectors have been developed to silence
genes in tumours. A retroviral vector has demonstrated
silencing of HER-2/neu [11]. Lentiviral vectors have
been employed to silence a number of tumour-
associated genes, including Tiam1, resulting in suppres-
sion of cancer cell growth in vitro and in vivo [12].
Similar inhibition of tumour cell growth has been
achieved by adenoviruses expressing shRNA against
ASH1, p28GANK, Skp-2 and Hec1 [13-15]. Further-
more, herpes simplex virus (HSV) amplicon vectors
have been shown to silence genes in tumour cells both
in vitro and in vivo [16,17].
Replicating viruses engineered to exhibit selective
tumour cytotoxicity have a significant advantage over
non-replicating viruses. A number of oncolytic viruses
are currently under clinical development for cancer ther-
apy. Thus, there is considerable interest in expressing
shRNA from these viruses to improve their tumour kill-
ing properties. Oncolytic adenovirus expressing shRNA
against the firefly luciferase transgene achieved 30% silen-
cing in a number of tumour cell lines [18]. More recently,
replication-competent adenoviruses expressing shRNA
against vascular endothelial growth factor (VEGF) and
Interleukin-8 (IL-8) have been shown to affect angiogen-
esis and inhibit tumour growth [19,20].
OncoVEX is a second-generation oncolytic HSV-1 with
deletion in ICP34.5 to provide tumour selective replica-
tion [21,22] and deletion of ICP47 resulting in the
expression of the US11 gene as an immediate-early (IE)
rather than a late (L) gene to further increase tumour
replication [23]. Infection of cells with wild type HSV
reduces antigen expression on the cell surface through
the expression of ICP47, which inhibits the transporters
associated with antigen presentation (TAP) [24,25].
Therefore, deletion of ICP47 would be expected to
increase the anti-tumour immune response in the pre-
sence of HSV [26,27]. This oncolytic HSV-1 backbone
has demonstrated improved tumour shrinkage properties
compared to previously developed oncolytic viruses and
has been used to successfully express a range of thera-
peutic genes in pre-clinical testing, including granulocyte
macrophage colony-stimulating factor (GM-CSF), retro-
viral glycoprotein, pro-drug activating system, and
Tumor Necrosis Factor-Alpha (TNFa) [28-30]. OncoV-
EX
GM-CSF has been further tested in Phase I and Phase II
clinical trials by direct injection into a number of tumour
types with promising results [31], and has entered Phase
III clinical studies in melanoma. While enhanced activity
has been observed when therapeutic genes have been
inserted into oncolytic HSV-1 genomes, expression of
shRNA had not been previously investigated.
Following the promising pre-clinical and clinical
results with OncoVEX, the current study aimed to iden-
tify whether it was possible to express shRNA and artifi-
cial miRNA from an oncolytic HSV backbone. To this
end, we developed viruses expressing shRNA or pre-
miRNA against b-galactosidase (lacZ) or enhanced
green fluorescent protein (eGFP) and evaluated the
potential of these vectors both in vitro and in vivo.W e
demonstrate, for the first time, that shRNA and artificial
miRNA can be expressed from an oncolytic HSV virus
and results in effective silencing of reporter genes in
vitro in non-tumour cells that are highly susceptible and
tumour cells that are moderately susceptible to HSV
infection and in vivo in tumours that are not cured by
oncolytic virus treatment alone. Ultimately, by down
regulating the levels of proteins secreted by tumour
cells, which aid their growth or promote local immune
suppression, we may further improve tumour cell killing
by oncolytic HSV in tumours that are moderately sus-
ceptible to HSV oncolysis. In the clinical situation, this
is expected to increase the response rates seen. For
example, in melanoma, response rates were approxi-
mately 30% in a phase II clinical trial and therefore,
increasing this rate of response using RNAi, or other
approaches, would be clearly clinically beneficial.
Methods
Cell lines
All cell lines were obtained from either ATCC or
ECACC or produced by the authors and were grown at
37°C in recommended media under a humidified atmo-
sphere of 5% CO2. The following cell lines were used:
BHK-21 (clone 13) (85011433), BHK-21 LacZ [32] and
9L lacZ (ATCC-CRL-2200) [33].
Construction and characterisation of viral vectors
Production of the oncolytic vector OncoVEX is
described by ref. 26. The cassettes expressing shRNA or
artificial miRNA against lacZ or enhanced green fluores-
cent protein (eGFP) are described by ref. 32. They
express shRNA and pre-miRNA sequences from the U6
polymerase III and CMV polymerase II promoters,
respectively. The pR19 cassette is flanked by HSV-1
LAT sequences.
B-galactosidase activity assay
B-galactosidase enzyme activity was assessed using high
sensitivity b-galactosidase assay kit (Stratagene). BHK-
LacZ cells were plated at 1.5×10
5 cells per well of
24-well tray and incubated at 37°C overnight. Cells were
infected with Onc miR-LacZ, Onc miR-neg, Onc
U6shLacZ and Onc U6shGFP at multiplicity of infection
(MOI) of 1, 0.1 and 0.01 and incubated at 37°C for
24 hours. Cells were freeze-thawed in lysis buffer and
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Page 2 of 11spun at 12,0000 g for 5 mins to remove cell debris. 20
ul of each cell lysate was added to the wells of a 96 well
micotiter ELISA dish (IWAKI ELISA). 130 ul of chloro-
phenol red-b-D-galactopyranoside substrate was added
and the samples were incubated at 37°C until the sub-
strate colour changed from yellow to brown. The reac-
tions were terminated by 80 ul of stop solution. The
plate was read using an OPSYS MR plate reader
(DYNEX technologies) at OD
570-595.
Western blot analysis
B-galactosidase protein levels were assessed by standard
Western blot techniques, performed on 20 ug of protein
per sample and using primary antibodies: b-galactosi-
dase (Abcam; ab616), a-tubulin (Abcam; ab4074) and
secondary antibody: goat polyclonal to rabbit IgG-H&L-
HRP (Abcam).
In vivo xenograft tumour models
All experimental procedures were performed with the
authority of the Home Office, following UK guidelines
and in accordance with best animal practice. Rat 9L/
LacZ cells were implanted (1×10
7 cells) subcutaneously
i nt h er i g h tf l a n ko fB A L B / cn u d em i c e( H a r l a nl a b o r a -
tories). Tumours were allowed to develop for 15 days to
an average diameter of approximately 0.4-0.6 cm and
then injected with 10
8 pfu (100 μl) of either Onc miR-
LacZ or Onc miR-neg, and further incubated for 72 hrs.
B-galactosidase protein levels were either assessed by
standard Western blot techniques or high sensitivity
b-galactosidase assay kit (Stratagene).
MTS cell viability assay and viral growth curves
BHK-LacZ cells, were seeded in 96-well plates at a den-
sity of 2.5×10
4 cells per well and incubated at 37°C O/N.
Cells were infected with Onc miR-LacZ, Onc U6shLacZ
or Oncovex backbone at a multiplicity of infection (MOI)
of 1, 0.1 and 0.01, and incubated at 37°C for 24, 48 and
72 hours. At each time point the supernatants were
removed (stored at -80°C) and the viral titre was deter-
mined using a standard viral plaque assay. Cell viability
was determined using the CellTiter 96 AQueous One
Solution Cell Proliferation Assay reagent 3-(4, 5-
dimethylthiazol-2-yl) -5- (3-carboxymethoxyphenyl) -2-
(4-sulfophenyl) -2H- tetrazolium) (MTS) according to
the manufacturer’s instructions (Promega). Briefly, 20 μL
of MTS reagent were added to each well together with
180 ul 2% FCS, RMPI, followed by incubation at 37°C for
15 min - 4 hours. Absorbance was measured at 495 nm.
Survival was calculated as a percentage of the measure-
ments taken in untreated cells.
Results
Development of oncolytic HSV RNAi viruses
The polymerase III U6 promoter has been most com-
monly used to express shRNA from plasmid and viral
vector systems. However, shRNA can be efficiently
expressed from the CMV polymerase II promoter when
embedded into endogenous miRNA sequences and
these artificial miRNAs have been shown to induce spe-
cific degradation of target mRNAs similar to transfected
siRNAs [34-36]. The microRNA-like expression system
used in this study is based on miR-155 and takes advan-
tage of the flexibility and variety of polymerase II pro-
moters, which unlike polymerase III promoters, can be
inducible and tissue-specific [37]. A reporter gene
encoding emerald GFP is co-expressed from this system
and allows labelling of transduced cells to aid the moni-
toring of silencing efficiency.
RNAi viruses based on the OncoVEX oncolytic HSV
backbone [28-30] were constructed by inserting cas-
settes expressing shRNA or miRNA against the gfp or
lacZ reporter genes into the latency associated transcript
(LAT) region of the HSV genome (Figure 1a). Expres-
sion of shRNA and pre-miRNA was driven by the U6
polymerase III and CMV polymerase II promoters,
respectively. These RNAi cassettes have been described
previously and showed highly effective and specific
silencing of reporter and endogenous gene expression in
neurons, when inserted into replication-defective HSV-1
vectors [32].
Oncolytic HSV can mediate expression of shRNA
To identify whether shRNA could be expressed from an
oncolytic HSV, BHK cells were co-infected with a non-
replicating HSV vector expressing eGFP (HSV
CMVeGFP) and either the oncolytic virus Onc
U6shGFP expressing shRNA against GFP or Onc
U6shLacZ expressing shRNA against b-galactosidase, at
an MOI 1.0. BHK cells are highly susceptible to HSV
infection and at 24 hrs over 90% of cells are GFP posi-
tive. Furthermore, whilst the majority of cells are
infected with replicating HSV (cells with rounded mor-
phology), only very few dead cells were detected in the
media and the cultures appeared healthy. At 24 hrs
post-infection, cells infected with Onc U6shGFP showed
a significant reduction in GFP expression levels com-
pared to the negative control (Figure 1b). Onc
U6shLacZ failed to reduce GFP expression indicating
that the silencing observed is not mediated by a non-
specific effect caused by the oncolytic HSV backbone.
We can therefore conclude that it is possible to express
active shRNA from an oncolytic HSV virus.
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Page 3 of 11Figure 1 Construction and characterisation of oncolytic HSV viruses expressing shRNA.( a) Schematic representation of the oncolytic HSV
genome and RNAi expression cassettes used in this study. Generation of OncoVEX viruses is described by Liu et al., 2003 and generation of
replication-defective HSV-1 vectors is described by Anesti et al., 2008. (b) BHK cells were dually infected with a non-replicating HSV CMVeGFP
virus and either Onc U6shGFP or Onc U6shLacZ, at an MOI of 1.0, and incubated for 24 hrs. The cells were digitally photographed using an UV-
inverted microscope (Nikon Eclipse TE200) and Lucia Imaging (MV-1500 version 4.6). (c,d,e) BHK-LacZ cells
29 were infected at various MOIs (1,
0.1, and 0.01) with oncolytic HSV viruses expressing shRNA (Onc U6shLacZ) or pre-miRNA (Onc miR-LacZ) against lacZ, or the negative control
viruses Onc U6shGFP and Onc miR-neg. Infected cells were harvested at 24, 48 and 72 hrs and b-galactosidase protein levels were assessed by
high sensitivity b-galactosidase assay (Stratagene). B-galactosidase levels (%LacZ) were expressed as a percentage of the expression measured in
the cells infected with the negative controls (Onc U6shGFP for Onc U6shLacZ, and Onc miR-neg for Onc miR-Lac. (f) B-galactosidase activity
(units/ml) in BHK-LacZ cells infected with Onc U6shGFP and Onc miR-neg control viruses at an MOI 1.0, and incubated for 24 hrs, 48 hrs and 73
hrs, or at an MOI 1.0, 0.1 and 0.01, and incubated at 72 hrs. BHK-LacZ cells constitutively express lacZ and thus, b-galactosidase levels are a good
indication of cell survival. All P values were obtained using unpaired student t test. (g) BHK-LacZ cells were infected with OncoVEX, Onc
U6shLacZ or Onc miR-LacZ at an MOI of 1.0, 0.1 and 0.01. MTS cell viability assay was performed at 24, 48 and 72 hours post-infection. Cell
death increases with time and MOI of virus. Expression of shLacZ or miR-LacZ does not significantly affect cytotoxicity caused by the oncolytic
virus. (h) BHK-LacZ cells were infected with OncoVEX, Onc U6shLacZ or Onc miR-LacZ. Growth curves were prepared by counting plaque
forming units at 24, 48 and 72 hours post-infection. Expression of shLacZ or miR-LacZ does not significantly influence the growth of the
oncolytic virus.
Anesti et al. BMC Cancer 2010, 10:486
http://www.biomedcentral.com/1471-2407/10/486
Page 4 of 11Evaluation of oncolytic HSV-mediated expression of
shRNA and miRNA
To optimise silencing from oncolytic HSV, we compared
viruses expressing shRNA or artificial miRNA against b-
galactosidase from the U6 (Onc U6shLacZ) and CMV
(Onc miR-LacZ) promoters, respectively. Onc U6shGFP
and Onc miR-neg, which expresses a non-target pre-
miRNA sequence under the control of the CMV promo-
ter, were used as negative controls. These viruses were
tested on the BHK-LacZ cell line, which constituently
expresses b-galactosidase and is highly susceptible to
HSV infection [32].
To investigate the properties of oncolytic HSV expres-
sing shRNA or miRNA, we performed an MTS cell via-
bility assay at 24, 48 and 72 hours on BHK-LacZ cells
infected with the oncolytic backbone virus OncoVEX,
Onc U6shLacZ or Onc miR-LacZ at MOIs 1.0, 0.1 and
0.01. Furthermore, we prepared growth curves for these
v i r u s e su s i n gt h es a m et i m ep o i n t s .F i g u r e s1 ga n d1 h
demonstrate that expression of shRNA/miRNA from the
LAT region does not significantly influence the cyto-
pathic effect and growth properties of oncolytic HSV,
respectively. Figure 1g further demonstrates that cell
death increases with time and MOI of virus.
BHK-LacZ cells infected with Onc U6shLacZ, Onc
miR-LacZ or each of the negative controls (Onc
U6shGFP and Onc miR-neg) at an MOI of 1.0, 0.1 and
0.01 were assayed for b-galactosidase expression at 24,
48 and 72 hours post-infection. At each MOI and time
point tested, the number of cells and concentration of
virus in each culture remain the same. Silencing of lacZ
does not affect the cytopathic effect of the virus (Figure
1g) and thus, cell survival in cultures treated with con-
trols, Onc U6shLacZ or Onc miR-LacZ is expected to
be the same in each one of the conditions. To compare
silencing between conditions with different levels of cell
survival, b-galactosidase levels (% LacZ) were expressed
as a percentage of the expression measured in the cells
infected with the negative controls (Onc U6shGFP for
Onc U6shLacZ, and Onc miR-neg for Onc miR-LacZ).
Analysis of b-galactosidase expression using enzyme
activity assay revealed that both viruses which targeted
lacZ significantly reduced b-galactosidase expression
levels compared to the negative control viruses at most
MOIs and timepoints tested, with the virus expressing
artificial miRNA being consistently more effective than
the virus expressing shRNA (Figure 1c,d,e).
At the earliest time point tested (24 hours), the most
effective silencing occurred at the highest MOI of 1.0
(Onc U6shLacZ: 52.2% silencing; Onc miR-LacZ: 72.1%
silencing, P = 0.0012), whereas the least effective silen-
c i n gw a so b s e r v e da tt h el o w e s tM O Io f0 . 0 1( O n c
U6shLacZ: 1.3% silencing; Onc miR-LacZ: 11.0% silen-
cing, P = 0.0033) (Figure 1c). At 48 hours post-infection,
both viruses resulted in increased b-galactosidase knock-
down at all MOIs tested compared to the negative con-
trols. However, the most effective silencing occurred at
the lower MOI of 0.1 (Onc U6shLacZ: 69.7% silencing;
Onc miR-LacZ: 80.0% silencing, P = 0.003) (Figure 1d).
At 72 hours post-infection, silencing at the high MOIs
was further reduced and the most effective silencing was
observed with Onc miR-LacZ at an MOI of 0.01 (80.0%
silencing) (Figure 1e).
Figure 1f demonstrates b-galactosidase activity levels in
cells infected with Onc U6shGFP and Onc miR-neg con-
trol viruses. All BHK-LacZ cells constituently express
b-galactosidase and thus, b-gal activity levels are a good
indication of the number of cells that have survived at
each MOI and time point. As expected from figure 1g,
b-galactosidase levels decrease with time and MOI of
virus. At an MOI 1.0, silencing is optimal at 48 hrs,
when half of the cells in the culture remain healthy, and
minimal at 72 hrs, when the majority of cells are killed
by the virus. At an MOI 0.01, however, optimal silencing
is achieved at 72 hrs, because the majority of cells in the
culture remain healthy. Since b-galactosidase levels in
BHK-LacZ cells infected with negative controls appear to
decrease with time and MOI of virus (Figure 1f) as a
result of cell death induced by the oncolytic backbone
(Figure 1g) and neither the cytotoxicity nor the growth of
oncolytic HSV are significantly affected by expression of
RNAi triggers (Figure 1g and 1h), a significant further
reduction in the levels of b-galactosidase in cells infected
with oncolytic HSV expressing either shLacZ or miR-
LacZ (Figures c, d and e) can only be attributed to an
RNAi-specific effect.
Collectively, the above results indicate that in order to
achieve optimal levels of silencing from a replicating
HSV, it is important to balance the levels of shRNA/
miRNA expression against cytotoxicity caused by the
virus. Insertion of the same shRNA and miRNA expres-
sion cassettes in the LAT region of replication-defective
HSV viruses resulted in expression of RNAi triggers in
BHK-LacZ cells in the complete absence of viral replica-
tion [32]. Although expression of RNAi triggers from
the LAT region is not dependant on viral replication,
the initial number of cells infected and number of viral
particles per cell (i.e. MOI) will determine the rate at
which RNAi triggers are expressed. As viral genome
copies increase exponentially and cell growth rate
decreases, even at very low MOIs, the virus will even-
tually infect all the cells in the culture and complete
cytopathic effect (CPE) will be achieved. At high MOIs,
high levels of RNAi triggers are expressed at early time
points, but if the MOI is too high, the cells may not
remain healthy long enough to allow the RNAi triggers
to act. Conversely, at low MOIs, high levels of RNAi
triggers will be expressed at later time points, but the
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to induce effective silencing.
Finally, expression of miRNA from the CMV polymer-
ase II promoter silenced target gene expression more
efficiently than expression of shRNA from the U6 poly-
merase III promoter at every time point and MOI tested
(unpaired student t tests). These results contrast with
data in BHK-LacZ cells using non-replicating HSV
expressing shRNA or miRNA from the same cassettes,
which showed no significant difference between shRNA
expressed from different promoters [32]. On the basis of
these results Onc miR-LacZ was used for the in vitro
and in vivo tumour cell studies described below.
Oncolytic HSV-mediated silencing in glioma cells in
culture
Oncolytic HSV has been shown to infect a wide range of
tumour cell types, including glioma [38-42], colon carci-
noma [43], prostate cancer [44,45], non-small cell lung
cancer [46], gallbladder carcinoma [47], head and neck
squamous cell carcinoma [48], oesophageal adenocarci-
noma [49], breast cancer [50], thyroid cancers [51],
hepatocellular carcinoma [52] and neuroblastoma
[53,54], with variable efficiencies. The HSV genome,
therefore, potentially offers a multifunctional platform
from which to knockdown tumour-related transcripts,
which could be used to help limit tumour immune sup-
pression or tumour growth as a whole.
The 9L/lacZ rat gliosarcoma cell line was developed
from the parental 9L cell line by transduction with the
BAG replication-deficient retroviral vector carrying the
E. coli lacZ gene. These cells constitutively express high
levels of b-galactosidase from the 9L genome and are
moderately susceptible to HSV infection [30]. Moder-
ately susceptible tumour cells allow HSV entry and
replication, but at a much lower rate than that required
for effective tumour killing. As a result, a lower number
of cells in a tumour will get infected by the virus at any
given dose than in more susceptible cell types. While
the virus will eventually kill infected cells, the process is
slower. The lower level of viral replication will also
result in a lower number of infectious particles being
released to infect neighbouring tumour cells. When the
kinetics of tumour cell killing do not exceed tumour
growth, expression of shRNA or miRNA in combination
to the viral cytopathic effect may be beneficial. Expres-
sion of RNAi triggers from the LAT region is not
dependant on viral replication and will therefore result
in the production of numerous silencing molecules from
a single viral genome copy, which has the potential to
improve the oncolytic properties of HSV by compensat-
ing for low viral particle numbers. Furthermore, the
oncolytic process is slower, which may allow silencing
molecules to accumulate and induce effective silencing
of targeted genes before infected cells are killed by the
virus. We have previously shown in vivo that OncoVEX
replication inhibits the growth of 9L tumours in the
flanks of nude F344 rats but fails to cure the tumours
[30]. Similar results were obtained with this virus in
RG2 glioma cells. Furthermore, expression of prodrug
activation genes from this oncolytic backbone enhanced
the cytopathic effect of the virus in 9L cells [30]. 9L
cells are therefore an appropriate model in which to test
oncolytic HSV-mediated silencing.
To test whether expression of miRNA from oncolytic
HSV could achieve silencing in tumour cells in culture,
we infected the 9L/LacZ cells with Onc miR-LacZ or
Onc miR-neg, at an MOI of 1.0, 5.0 and 10.0. Optimal
silencing in BHK cells was achieved at 48 hrs, MOI 0.1.
9L cells are moderately susceptible to HSV infection
compared to BHK cells and thus, considerably higher
MOIs were used. B-galactosidase activity assay at 48 hrs
post-infection demonstrated 62.5% silencing at MOI 1.0
(P = 0.0007), 34.7% silencing at MOI 5.0 (P = 0.0001)
and no silencing at MOI 10.0 (Figure 2b). Figure 2b
further demonstrates that 5 times more cells were killed
by the virus at MOI 5.0 compared to MOI 1.0, and
1.5 times more cells were killed at MOI 10.0 compared
to MOI 5.0. To investigate the reason lacZ silencing
achieved in these cells was moderate compared to silen-
cing in BHK-LacZ cells, we assessed the levels of GFP
expressed from miR viruses that enable direct labelling
of infected cells. Fluorescent microscopy in 9L/LacZ
infected with Onc miR-neg at 48 hrs revealed that
o n l yap r o p o r t i o no fc e l l sa r ei n f e c t e da ta nM O I1 . 0
(Figure 2a). At MOIs 5.0 and 10.0, nearly all cells in the
cultures are killed by the virus (data not shown). Thus,
that optimal silencing in 9L cells at 48 hrs can be
achieved between MOI 1.0 and 5.0, i.e. at considerably
higher doses than those needed to achieve near com-
plete silencing in a highly susceptible cell line.
The above data revealed that expression of miRNA
from an oncolytic HSV virus can induce silencing in a
tumour cell line. Although the 9L/LacZ rat glioma cell
line is infected with relatively low efficiency and thus,
lacZ is only partially silenced, this cell line is an appro-
priate model to study oncolytic HSV-mediated silencing,
as silencing is expected to be particularly useful in
tumours which are less efficiently infected by the virus
and thus, not completely killed by oncolytic HSV
treatment.
Oncolytic HSV-mediated silencing in tumours in vivo
To investigate oncolytic HSV-mediated silencing in
tumours in vivo,w ei n j e c t e dt h ef l a n k so fn u d em i c e
with 9L/LacZ cells and allowed tumours to develop. The
resulting tumours were injected with 10
8 pfu of either
Onc miR-LacZ or Onc miR-neg and were analysed for
Anesti et al. BMC Cancer 2010, 10:486
http://www.biomedcentral.com/1471-2407/10/486
Page 6 of 11b-galactosidase expression by Western blot and enzyme
activity assay 72 hrs post-injection. Quantitative RT-
PCR revealed similar levels of GFP transcripts within
tumours injected with either virus (data not shown).
Western blot analysis of tumours isolated from animals
injected with Onc miR-LacZ (n = 4) demonstrated
knockdown of b-galactosidase levels compared to
tumours injected with Onc miR-neg (n = 2) (Figure 2c).
Moderate reduction in protein levels is difficult to con-
vincingly demonstrate using western blot. Furthermore,
b-galactosidase is highly expressed in 9L tumour cells
and has a very long half-life resulting in high back-
ground, which makes quantification of western blots
using band density very difficult. For these reasons,
knockdown of b-galactosidase was confirmed using b-
gal enzyme activity assay, which is quantitative and con-
siderably more sensitive than western blot. B-galactosi-
dase activity assay on the same tumours revealed that
non-injected tumours expressed the highest levels of b-
galactosidase (n = 2), injection with Onc miR-neg
resulted in an average 19.4% silencing of lacZ (n = 2)
compared to non-injected tumours (P = 0.005), and
injection with Onc miR-LacZ resulted in 49 ± 5.9%
silencing of lacZ (n = 4) compared to tumours injected
with the Onc miR-neg control (P = 0.0001) (Figure 2d).
We have previously shown that the oncolytic virus used
in this study can inhibit the growth of 9L tumours in
the flanks of F344 rats [30]. Therefore, we can conclude,
that the 19.4% difference in the levels of b-galactosidase
between non-injected tumours and tumours injected
with miR-neg control is due to oncolysis caused by the
viral backbone. 49% silencing in tumours in vivo is a
highly promising result bearing in mind that 9L/LacZ
cells are moderately susceptible to HSV infection. These
results indicate that an oncolytic HSV expressing
shRNA/miRNA has the potential to silence target gene
expression in tumours in vivo, which had not been pre-
viously demonstrated.
Discussion
Unlike oncolytic adenoviral vectors, which replicate at a
very slow rate and have been shown to induce RNAi in
tumours [18-20], replicating HSV was not considered a
suitable vector from which to express RNAi triggers,
because it is robustly oncolytic. This study is the first to
show oncolytic HSV-mediated expression of shRNA and
artificial miRNA. Our results demonstrate effective and
specific silencing of a reporter gene in tumour cells
both in vitro and in vivo.W ea l s od e m o n s t r a t et h a t
expression of shRNA from an oncolytic HSV backbone
can be driven from either a polymerase II or III promo-
ter, although expression from the CMV promoter was
comprehensibly more effective. The use of artificial miR-
NAs has become a very attractive alternative to the
expression of shRNA. Artificial miRNAs are amenable
to RNA polymerase II transcription and polycistronic
strategies, which allow delivery of multiple shRNA
sequences simultaneously and co-expression of a
Figure 2 Silencing in glioma cells in vitro and in vivo. (a) Rat 9L/
LacZ [30] cells were infected at an MOI of 1.0 with Onc miR-neg
and incubated for 48 hrs. GFP levels were assessed by fluorescent
microscopy. (b) Rat 9L/LacZ cells were infected at an MOI of 1.0, 5.0
and 10.0 with Onc miR-LacZ or Onc miR-neg, and incubated for 48
hrs. B-galactosidase protein levels (units/ml) were assessed using
high sensitivity b-galactosidase assay (Stratagene). P values were
obtained using unpaired student t test. (c,d) Rat 9L/LacZ cells were
implanted (1×10
7 cells) subcutaneously in the right flank of BALB/c
nude mice (Harlan laboratories). Tumours were allowed to develop
for 2 weeks to an average diameter of approximately 0.4-0.6 cm
and then injected with 10
8 pfu (100 μl) of either Onc miR-LacZ or
Onc miR-neg, and further incubated for 72 hrs. B-galactosidase
protein levels were either assessed by standard (c) Western blot
techniques or (d) high sensitivity b-galactosidase assay kit
(Stratagene).
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the shRNA.
Furthermore, we show that oncolytic HSV-mediated
silencing can be achieved in cell types that are either
highly susceptible or moderately susceptible to HSV
infection. We show that when oncolytic HSV is given at
the right dose, shRNA can be expressed and effective
silencing can be induced in an infected cell, before the
cell is killed by the virus. Thus, delivery of RNAi to
tumours using oncolytic HSV provides the potential to
improve tumour cell killing by silencing tumour-related
genes. For example, induction of RNAi in combination
with the virus oncolytic effect may be able to improve
response rates seen in human clinical trials with oncoly-
tic viruses. Moreover, expression of shRNA from onco-
lytic HSV may be useful in enhancing cell killing in
tumours that are relatively less susceptible to HSV infec-
tion. We show that expression of RNAi triggers from
the LAT region, which is not dependant on viral replica-
tion, is sufficient to induce silencing of a target gene
despite a low viral particle number in tumours where
HSV infection and/or replication are moderate. When
the shRNA or miRNA is engineered to target proteins
secreted by tumour cells, which aid their growth or pro-
mote local immune suppression, moderate silencing in
these tumours may be sufficient to promote cell death
in both infected and non-infected cells in a tumour.
As the process of lytic virus replication is effective at
destroying injected tumours, the most appropriate tar-
gets for RNAi-mediated knockdown using this approach
would be expected to be secreted tumour proteins
involved in processes such as angiogenesis or local
immune suppression. Vascular endothelial growth factor
(VEGF) is a key regulator of angiogenesis. Up-regulation
of VEGF is important in blood vessel formation in solid
tumours [55] and mediates tumour evasion of immune
surveillance by inhibiting the development of dendritic
and other hematopoetic cells [56]. In recent years,
numerous studies have demonstrated that silencing of
VEGF by non-viral-mediated delivery of siRNA leads to
reduction in tumour size of up to 90% [57-60]. To
improve delivery of RNAi triggers against VEGF, non-
replicating viruses were generated [61,62]. More
recently, replication-competent adenoviruses expressing
shRNA against VEGF and Interleukin-8 were shown to
affect angiogenesis and inhibit tumour growth [19,20].
Other factors secreted by tumours, such as Interleukin-
10 (IL-10) and transforming growth factor-b (TGF-b),
are attractive targets for knockdown using oncolytic
HSV. IL-10 is an anti-inflammatory, immunosuppressive
cytokine that is involved in tumour escape from
immune surveillance [63]. Elevated IL-10 levels have
been found in a variety of human malignant tumours
and are an independent prognosis factor for decreased
response to chemotherapy in patients with advanced
gastrointestinal malignancies [64,65]. In a malignant B-1
cell line derived from a murine model of chronic lym-
phocytic leukaemia, induction of RNAi against IL-10
resulted in anti-proliferative and pro-apoptotic effects
[66]. TGF-b is a multifunctional polypeptide which
switches its role from a tumour suppressor in normal
cells to a tumour promoter in advanced cancers. TGF-b
protein-receptor interactions promote processes such as
immune suppression, tissue remodelling and formation
of blood vessels, which lead to the growth and metasta-
sis of cancer cells [67]. TGF-b is the prototypic member
of a large superfamily of secreted proteins that include
three TGF-b isoforms (TGF-b1, TGF-b2a n dT G F - b3).
Antisense oligonucleotides against TGF-b1 developed
for the treatment of non-small cell lung carcinoma, col-
orectal and prostate carcinomas have shown efficacy in
preclinical development [68]. Antisense oligonucleotides
against TGFb2 have been tested in a number of clinical
trials against various cancers, with promising results
[69].
Infection with wild-type HSV results in expression of
virion host shutoff protein (vhs), which leads to mRNA
degradation and shutdown of host cell protein synthesis.
However, whilst a proportion of cellular mRNAs that
mainly encode proteins involved in the cell immune
response to virus infection are degraded, microarray
analysis of gene expression has demonstrated that
almost 500 genes are up-regulated more than 3-fold in
HSV-1-infected cells, compared with mock-infected cells
[70]. Moreover, whilst expression of GFP from a non-
replicating HSV virus (Figure 1b) is not likely to be
affected by vhs, due to viral mRNA being transcribed at
a higher rate than cellular mRNA, we demonstrate that
lacZ, whose expression in 9L/LacZ cells resembles that
of an endogenous gene, is not affected by vhs and can
be specifically silenced both in vitro and in vivo
(described in figure 2). Thus, although expression of vhs
may alleviate the need to target certain cellular genes,
expression of shRNA from an oncolytic HSV has the
potential to allow specific silencing of genes that are not
downregulated by HSV infection itself.
Conclusion
In summary, the current study provides the first demon-
stration that an oncolytic HSV can be used to induce
RNAi to tumour cells in vitro and tumours in vivo.A
combination of oncolytic HSV and RNAi technology
offers the potential to further increase the effectiveness
of oncolytic HSV therapy by inhibiting genes involved in
tumour-related processes which may enhance the overall
anti-tumour effect, especially in tumours that are only
moderately susceptible to HSV replication. The vectors
described in this study are being engineered to target a
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Page 8 of 11selection of tumour-related genes, and experiments are
underway to investigate whether the effectiveness of
oncolytic virus treatment can be improved in tumours
moderately susceptible to HSV infection when these
targets are silenced.
Acknowledgements
The authors would like to thank Suzanne Thomas, Mark Rust and Caroline
Nash at BioVex.
Author details
1Research Group, Biovex Inc, Commerce Way, Woburn, MA1801, USA.
2Oncology Group, Postgraduate Medical School, University of Surrey, Surrey,
GU2 5XH, UK.
Authors’ contributions
AMA and GS have contributed equally to this work. GS constructed the
oncolytic viruses and performed all experiments described in figure 1. AMA
constructed the RNAi cassettes and performed all experiments described in
figure 2. TP produced a high titre preparation of the OncoVex miR-neg and
OncoVex miR-LacZ viruses. Authors AMA, GS, TP, HP, and RC had full access
to all the data in the study and take responsibility for the integrity of the
data and the accuracy of the data analysis. Study concept and design: AMA,
GS, and RC. Acquisition of data: AMA and GS. Analysis and interpretation of
data: AMA, GS, and RC. Drafting of the manuscript: AMA, GS, HP and RC.
Statistical analysis: GS. Study supervision: HP and RC. All authors read and
approved the final manuscript.
Competing interests
Dr. Guy Simpson is a former employee of BioVex Inc. (a commercial biotech
company) and has no shares or share options in the company. Dr. Simpson
left the company in April 2007. Dr. Anna-Maria Anesti is a former employee
of BioVex Inc. and has no shares or share options in the company. Dr. Anesti
has been a BioVex consultant since December 2008. Dr. Toby Price is an
employee of BioVex Inc. and has share options in the company. Prof. Hardev
Pandha is a physician and academic scientist with no commercial link to
BioVex Inc. Dr. Rob Coffin is the chief technical officer of BioVex Inc. with
both shares and share options in the company. BioVex Inc has funded the
work described in this manuscript.
Received: 17 December 2009 Accepted: 13 September 2010
Published: 13 September 2010
References
1. Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer.
Nat Rev Cancer 2006, 6:259-269.
2. Bernstein E, Caudy AA, Hammond SM, Hannon GJ: Role for a bidentate
ribonuclease in the initiation step of RNA interference. Nature 2001,
409:363-366.
3. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD: A
cellular function for the RNA-interference enzyme Dicer in the
maturation of the let-7 small temporal RNA. Science 2001, 293:834-838.
4. Zhang H, Kolb FA, Brondani V, Billy E, Filipowicz W: Human Dicer
preferentially cleaves dsRNAs at their termini without a requirement for
ATP. EMBO J 2002, 21:5875-5885.
5. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O,
Kim S, et al: The nuclear RNase III Drosha initiates microRNA processing.
Nature 2003, 425:415-419.
6. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U: Nuclear export of
microRNA precursors. Science 2004, 303:95-98.
7. Boudreau RL, Monteys AM, Davidson BL: Minimizing variables among
hairpin-based RNAi vectors reveals the potency of shRNAs. RNA 2008,
14:1834-1844.
8. Boudreau RL, Martins I, Davidson BL: Artificial microRNAs as siRNA
shuttles: improved safety as compared to shRNAs in vitro and in vivo.
Mol Ther 2009, 17:169-175.
9. Silva JM, Li MZ, Chang K, Ge W, Golding MC, Rickles RJ, Siolas D, Hu G,
Paddison PJ, Schlabach MR, et al: Second-generation shRNA libraries
covering the mouse and human genomes. Nat Genet 2005, 37:1281-1288.
10. Shen Y: Advances in the development of siRNA-based therapeutics for
cancer. IDrugs 2008, 11:572-578.
11. Yang G, Cai KQ, Thompson-Lanza JA, Bast RC Jr, Liu J: Inhibition of breast
and ovarian tumor growth through multiple signaling pathways by
using retrovirus-mediated small interfering RNA against Her-2/neu gene
expression. J Biol Chem 2004, 279:4339-4345.
12. Liu L, Zhang Q, Zhang Y, Wang S, Ding Y: Lentivirus-mediated silencing of
Tiam1 gene influences multiple functions of a human colorectal cancer
cell line. Neoplasia 2006, 8:917-924.
13. Osada H, Tatematsu Y, Yatabe Y, Horio Y, Takahashi T: ASH1 gene is a
specific therapeutic target for lung cancers with neuroendocrine
features. Cancer Res 2005, 65:10680-10685.
14. Li H, Fu X, Chen Y, Hong Y, Tan Y, Cao H, Wu M, Wang H: Use of
adenovirus-delivered siRNA to target oncoprotein p28GANK in
hepatocellular carcinoma. Gastroenterology 2005, 128:2029-2041.
15. Sumimoto H, Yamagata S, Shimizu A, Miyoshi H, Mizuguchi H, Hayakawa T,
Miyagishi M, Taira K, Kawakami Y: Gene therapy for human small-cell lung
carcinoma by inactivation of Skp-2 with virally mediated RNA
interference. Gene Ther 2005, 12:95-100.
16. Saydam O, Glauser DL, Heid I, Turkeri G, Hilbe M, Jacobs AH, Ackermann M,
Fraefel C: Herpes simplex virus 1 amplicon vector-mediated siRNA
targeting epidermal growth factor receptor inhibits growth of human
glioma cells in vivo. Mol Ther 2005, 12:803-812.
17. Sabbioni S, Callegari E, Manservigi M, Argnani R, Corallini A, Negrini M,
Manservigi R: Use of herpes simplex virus type 1-based amplicon vector
for delivery of small interfering RNA. Gene Ther 2007, 14:459-464.
18. Carette JE, Overmeer RM, Schagen FH, Alemany R, Barski OA, Gerritsen WR,
van Beusechem VW: Conditionally replicating adenoviruses expressing
short hairpin RNAs silence the expression of a target gene in cancer
cells. Cancer Res 2004, 64:2663-2667.
19. Yoo JY, Kim JH, Kwon YG, Kim EC, Kim NK, Choi HJ, Yun CO: VEGF-specific
short hairpin RNA-expressing oncolytic adenovirus elicits potent
inhibition of angiogenesis and tumor growth. Mol Ther 2007, 15:295-302.
20. Yoo JY, Kim JH, Kim J, Huang JH, Zhang SN, Kang YA, Kim H, Yun CO: Short
hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8:
effects on antiangiogenesis and tumor growth inhibition. Gene Ther 2008,
15:635-651.
21. Chou J, Roizman B: The herpes simplex virus 1 gene for ICP34.5, which
maps in inverted repeats, is conserved in several limited-passage
isolates but not in strain 17syn+. J Virol 1990, 64:1014-1020.
22. MacLean AR, ul-Fareed M, Robertson L, Harland J, Brown SM: Herpes
simplex virus type 1 deletion variants 1714 and 1716 pinpoint
neurovirulence-related sequences in Glasgow strain 17+ between
immediate early gene 1 and the ‘a’ sequence. J Gen Virol 1991, 72(Pt
3):631-639.
23. Taneja S, MacGregor J, Markus S, Ha S, Mohr I: Enhanced antitumor
efficacy of a herpes simplex virus mutant isolated by genetic selection
in cancer cells. Proc Natl Acad Sci USA 2001, 98:8804-8808.
24. Hill AB, Barnett BC, McMichael AJ, McGeoch DJ: HLA class I molecules are
not transported to the cell surface in cells infected with herpes simplex
virus types 1 and 2. J Immunol 1994, 152:2736-2741.
25. Jennings SR, Rice PL, Kloszewski ED, Anderson RW, Thompson DL,
Tevethia SS: Effect of herpes simplex virus types 1 and 2 on surface
expression of class I major histocompatibility complex antigens on
infected cells. J Virol 1985, 56:757-766.
26. Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, McGrath Y,
Thomas SK, Thornton M, Bullock P, et al: ICP34.5 deleted herpes simplex
virus with enhanced oncolytic, immune stimulating, and anti-tumour
properties. Gene Ther 2003, 10:292-303.
27. Todo T, Martuza RL, Rabkin SD, Johnson PA: Oncolytic herpes simplex
virus vector with enhanced MHC class I presentation and tumor cell
killing. Proc Natl Acad Sci USA 2001, 98:6396-6401.
28. Liu RB, Rabkin SD: Oncolytic herpes simplex virus vectors for the
treatment of human breast cancer. Chin Med J (Engl) 2005, 118:307-312.
29. Han ZQ, Assenberg M, Liu BL, Wang YB, Simpson G, Thomas S, Coffin RS:
Development of a second-generation oncolytic Herpes simplex virus
expressing TNFalpha for cancer therapy. J Gene Med 2007, 9:99-106.
Anesti et al. BMC Cancer 2010, 10:486
http://www.biomedcentral.com/1471-2407/10/486
Page 9 of 1130. Simpson GR, Han Z, Liu B, Wang Y, Campbell G, Coffin RS: Combination of
a fusogenic glycoprotein, prodrug activation, and oncolytic herpes
simplex virus for enhanced local tumor control. Cancer Res 2006,
66:4835-4842.
31. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, Harrington KJ,
James ND, Love CA, McNeish I, et al: A phase I study of OncoVEXGM-CSF,
a second-generation oncolytic herpes simplex virus expressing
granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006,
12:6737-6747.
32. Anesti AM, Peeters PJ, Royaux I, Coffin RS: Efficient delivery of RNA
Interference to peripheral neurons in vivo using herpes simplex virus.
Nucleic Acids Res 2008, 36:e86.
33. Lampson LA, Lampson MA, Dunne AD: Exploiting the lacZ reporter gene
for quantitative analysis of disseminated tumor growth within the brain:
use of the lacZ gene product as a tumor antigen, for evaluation of
antigenic modulation, and to facilitate image analysis of tumor growth
in situ. Cancer Res 1993, 53:176-182.
34. Zeng Y, Wagner EJ, Cullen BR: Both natural and designed micro RNAs can
inhibit the expression of cognate mRNAs when expressed in human
cells. Mol Cell 2002, 9:1327-1333.
35. Zeng Y, Cullen BR: Sequence requirements for micro RNA processing and
function in human cells. RNA 2003, 9:112-123.
36. Zeng Y, Yi R, Cullen BR: MicroRNAs and small interfering RNAs can inhibit
mRNA expression by similar mechanisms. Proc Natl Acad Sci USA 2003,
100:9779-9784.
37. Chung KH, Hart CC, Al-Bassam S, Avery A, Taylor J, Patel PD, Vojtek AB,
Turner DL: Polycistronic RNA polymerase II expression vectors for RNA
interference based on BIC/miR-155. Nucleic Acids Res 2006, 34:e53.
38. Chambers R, Gillespie GY, Soroceanu L, Andreansky S, Chatterjee S, Chou J,
Roizman B, Whitley RJ: Comparison of genetically engineered herpes
simplex viruses for the treatment of brain tumors in a scid mouse
model of human malignant glioma. Proc Natl Acad Sci USA 1995,
92:1411-1415.
39. Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY,
Roizman B, Whitley RJ: Evaluation of genetically engineered herpes
simplex viruses as oncolytic agents for human malignant brain tumors.
Cancer Res 1997, 57:1502-1509.
40. Andreansky SS, He B, Gillespie GY, Soroceanu L, Markert J, Chou J,
Roizman B, Whitley RJ: The application of genetically engineered herpes
simplex viruses to the treatment of experimental brain tumors. Proc Natl
Acad Sci USA 1996, 93:11313-11318.
41. Samoto K, Ehtesham M, Perng GC, Hashizume K, Wechsler SL, Nesburn AB,
Black KL, Yu JS: A herpes simplex virus type 1 mutant with gamma 34.5
and LAT deletions effectively oncolyses human U87 glioblastomas in
nude mice. Neurosurgery 2002, 50:599-605.
42. Detta A, Harland J, Hanif I, Brown SM, Cruickshank G: Proliferative activity
and in vitro replication of HSV1716 in human metastatic brain tumours.
J Gene Med 2003, 5:681-689.
43. Carroll NM, Chiocca EA, Takahashi K, Tanabe KK: Enhancement of gene
therapy specificity for diffuse colon carcinoma liver metastases with
recombinant herpes simplex virus. Ann Surg 1996, 224:323-329.
44. Cozzi PJ, Burke PB, Bhargav A, Heston WD, Huryk B, Scardino PT, Fong Y:
Oncolytic viral gene therapy for prostate cancer using two attenuated,
replication-competent, genetically engineered herpes simplex viruses.
Prostate 2002, 53:95-100.
45. Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD,
Martuza RL: Local and systemic therapy of human prostate
adenocarcinoma with the conditionally replicating herpes simplex virus
vector G207. Hum Gene Ther 1999, 10:2237-2243.
46. Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR, Molnar-Kimber KL:
Combined therapy with chemotherapeutic agents and herpes simplex
virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung
cancer. Hum Gene Ther 1999, 10:3013-3029.
47. Nakano K, Todo T, Chijiiwa K, Tanaka M: Therapeutic efficacy of G207, a
conditionally replicating herpes simplex virus type 1 mutant, for
gallbladder carcinoma in immunocompetent hamsters. Mol Ther 2001,
3:431-437.
48. Wong RJ, Kim SH, Joe JK, Shah JP, Johnson PA, Fong Y: Effective treatment
of head and neck squamous cell carcinoma by an oncolytic herpes
simplex virus. J Am Coll Surg 2001, 193:12-21.
49. Stiles BM, Bhargava A, Adusumilli PS, Stanziale SF, Kim TH, Rusch VW,
Fong Y: The replication-competent oncolytic herpes simplex mutant
virus NV1066 is effective in the treatment of esophageal cancer. Surgery
2003, 134:357-364.
50. Pin RH, Reinblatt M, Fong Y: Employing tumor hypoxia to enhance
oncolytic viral therapy in breast cancer. Surgery 2004, 136:199-204.
51. Yu Z, Eisenberg DP, Singh B, Shah JP, Fong Y, Wong RJ: Treatment of
aggressive thyroid cancer with an oncolytic herpes virus. Int J Cancer
2004, 112:525-532.
52. Pin RH, Reinblatt M, Fong Y: Utilizing alpha-fetoprotein expression to
enhance oncolytic viral therapy in hepatocellular carcinoma. Ann Surg
2004, 240:659-665.
53. Li H, Dutuor A, Tao L, Fu X, Zhang X: Virotherapy with a type 2 herpes
simplex virus-derived oncolytic virus induces potent antitumor immunity
against neuroblastoma. Clin Cancer Res 2007, 13:316-322.
54. Parikh NS, Currier MA, Mahller YY, Adams LC, Di PB, Collins MH, Cripe TP:
Oncolytic herpes simplex virus mutants are more efficacious than wild-
type adenovirus Type 5 for the treatment of high-risk neuroblastomas in
preclinical models. Pediatr Blood Cancer 2005, 44:469-478.
55. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor
is a potential tumour angiogenesis factor in human gliomas in vivo.
Nature 1992, 359:845-848.
56. Ohm JE, Carbone DP: VEGF as a mediator of tumor-associated
immunodeficiency. Immunol Res 2001, 23:263-272.
57. Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, Bennett J,
Tolentino MJ: Small interfering RNA (siRNA) targeting VEGF effectively
inhibits ocular neovascularization in a mouse model. Mol Vis 2003,
9:210-216.
58. Zhang L, Yang N, Mohamed-Hadley A, Rubin SC, Coukos G: Vector-based
RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-
angiogenesis gene therapy of cancer. Biochem Biophys Res Commun 2003,
303:1169-1178.
59. Detwiller KY, Fernando NT, Segal NH, Ryeom SW, D’Amore PA, Yoon SS:
Analysis of hypoxia-related gene expression in sarcomas and effect of
hypoxia on RNA interference of vascular endothelial cell growth factor
A. Cancer Res 2005, 65:5881-5889.
60. Senn C, Hangartner C, Moes S, Guerini D, Hofbauer KG: Central
administration of small interfering RNAs in rats: a comparison with
antisense oligonucleotides. Eur J Pharmacol 2005, 522:30-37.
61. Wang J, Shi YQ, Yi J, Ye S, Wang LM, Xu YP, He M, Kong XM: Suppression
of growth of pancreatic cancer cell and expression of vascular
endothelial growth factor by gene silencing with RNA interference. JD i g
Dis 2008, 9:228-237.
62. Lombardi G, Calistri A, Curtarello M, Giudice GL, Piermarocchi S,
Prosdocimo G, Palu G, Parolin C: HIV-1-mediated delivery of a short
hairpin RNA targeting vascular endothelial growth factor in human
retinal pigment epithelium cells. Br J Ophthalmol 2009, 93:244-248.
63. Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S, Burg G:
Interleukin-10 is a growth factor for human melanoma cells and down-
regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer
1997, 71:630-637.
64. O’Garra A, Chang R, Go N, Hastings R, Haughton G, Howard M: Ly-1 B (B-1)
cells are the main source of B cell-derived interleukin 10. Eur J Immunol
1992, 22:711-717.
65. O’Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C: Strategies for use
of IL-10 or its antagonists in human disease. Immunol Rev 2008,
223:114-131.
66. McCarthy BA, Mansour A, Lin YC, Kotenko S, Raveche E: RNA interference
of IL-10 in leukemic B-1 cells. Cancer Immun 2004, 4:6.
67. Nagaraj NS, Datta PK: Targeting the transforming growth factor-beta
signaling pathway in human cancer. Expert Opin Investig Drugs 2010,
19:77-91.
68. Saunier EF, Akhurst RJ: TGF beta inhibition for cancer therapy. Curr Cancer
Drug Targets 2006, 6:565-578.
69. Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T,
Steinbrecher A, Brawanski A, Proescholdt M, Schlaier J, Buchroithner J, et al:
Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas:
from preclinical to phase I/II studies. Oligonucleotides 2007, 17:201-212.
70. Taddeo B, Esclatine A, Roizman B: Post-transcriptional processing of
cellular RNAs in herpes simplex virus-infected cells. Biochem Soc Trans
2004, 32:697-701.
Anesti et al. BMC Cancer 2010, 10:486
http://www.biomedcentral.com/1471-2407/10/486
Page 10 of 11Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/486/prepub
doi:10.1186/1471-2407-10-486
Cite this article as: Anesti et al.: Expression of RNA interference triggers
from an oncolytic herpes simplex virus results in specific silencing in
tumour cells in vitro and tumours in vivo. BMC Cancer 2010 10:486.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Anesti et al. BMC Cancer 2010, 10:486
http://www.biomedcentral.com/1471-2407/10/486
Page 11 of 11